

08/087,132

Remarks

As suggested by the Examiners at the January 31, 1996 interview, the Specification is being amended to include text material and Figure 1 from Gregory et al., Nature, 347, 1990, pp.382-386. The Gregory et al. 1990 reference was referred to, and the T936C mutation was disclosed, in the Specification herein, as originally filed on November 15, 1990 at page 17, lines 18-22 therein. Figure 1 from Gregory et al. (copy enclosed) is being added to the Specification as new Figure 14. The text sections of Gregory et al that are being added to the Specification are found on page 382, column 1, and in the legend of Figure 1 on page 383. The subtitle sentence "Identification of the Active Cryptic Promoter Site" for which incorporation into Example 5 of the Specification was requested above is not original text, but is believed to be useful as a bridge between the old and new paragraphs. A few other additional lines of text added from Gregory et al. 1990 were modified slightly for stylistic reasons but no new matter was introduced thereby. The Gregory et al. 1990 article also contained a typographical error which is very obvious by context, and this has been corrected where incorporated into the Specification. In this regard, the examiner's attention is directed to p. 382 , column 1 of the article, at text line 15 where "segments of CFTR" should have read -- segments of CFTR cDNA--.

08/087,132

The Gregory et al. 1990 reference has also been discussed at length in Applicants' submissions herein, including for example, Declaration "D" of Richard Gregory submitted June 9, 1995, and to which a copy of the 1990 article was attached.

Reference in the Specification to the subject matter of new claims 216 and 218 (that is, plasmid pSC-CFTR2 and host *E. coli* cells pSC-CFTR2/AG1, ATCC 68244) is found at page 13, lines 6-25. Applicants note also that at page 13, line 22 of their Specification, reference is made to a single nucleotide sequencing error of Riordan et al 1989 at position 1991 in the cDNA.

#### Conclusion

No fees are believed to be due for the new claims since both the number of independent claims and the number of total claims that are added hereinby are less than the numbers thereof that have been canceled previously. No Request for an Extension of Time is believed to be due in connection with this Reply since it is a supplemental reply. However, should the Patent Office determine that any fees are due, then the Patent Office is authorized to charge to **Deposit Account 07-1074** the additional claim fee, or any other fee, that it determines is necessary to secure the filing of this Amendment or entry of the new claims.

08/087,132

Applicants believe that the application is fully in condition for allowance, and that all pertinent issues have been addressed. It is respectfully requested that the claims now be passed to allowance. The Examiner is invited to phone the undersigned at (508) 872-8400 to discuss any matters that she believes require further attention. Applicants herein would again like to acknowledge the Examiners' efforts on behalf of the application, and the medically important discoveries that are described therein. An early and favorable action is respectfully requested.

Respectfully submitted,

GENZYME CORPORATION

By: 

Elizabeth Lassen  
Reg. No. 31, 845  
E. Victor Donahue  
Reg. No. 35,492

Dated: April 2, 1996

One Mountain Road  
Framingham, MA 01701-9322  
(508) 872-8400

Rochelle K. Seide  
Reg. No. 32,300  
Brumbaugh, Graves, Donohue &  
Raymond, Of Counsel

30 Rockefeller Plaza  
New York, NY 10112-0228  
(212) 408-2626